These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20405247)

  • 1. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
    Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
    Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
    Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
    J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
    Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
    Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
    Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
    J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
    Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
    Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are CD44
    Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
    Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-erbB-2 and the "triple-state" in early breast carcinomas.
    Sivridis E; Stamos C; Fiska A; Nikolettos N; Koukourakis MI; Giatromanolaki A
    Med Oncol; 2010 Sep; 27(3):578-84. PubMed ID: 19548127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
    Honeth G; Bendahl PO; Ringnér M; Saal LH; Gruvberger-Saal SK; Lövgren K; Grabau D; Fernö M; Borg A; Hegardt C
    Breast Cancer Res; 2008; 10(3):R53. PubMed ID: 18559090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High GD2 expression defines breast cancer cells with enhanced invasiveness.
    Mansoori M; Roudi R; Abbasi A; Abolhasani M; Abdi Rad I; Shariftabrizi A; Madjd Z
    Exp Mol Pathol; 2019 Aug; 109():25-35. PubMed ID: 31075227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the correlation factors on CD44+ CD24-/low ESA+ Lin- cell ratio in breast cancer].
    Wang R; Yang XQ; Lü Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 45(1):53-6. PubMed ID: 24527582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
    Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
    Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas.
    Oliveira-Costa JP; Zanetti JS; Silveira GG; Soave DF; Oliveira LR; Zorgetto VA; Soares FA; Zucoloto S; Ribeiro-Silva A
    Diagn Pathol; 2011 Aug; 6():73. PubMed ID: 21824412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
    Perrone G; Gaeta LM; Zagami M; Nasorri F; Coppola R; Borzomati D; Bartolozzi F; Altomare V; Trodella L; Tonini G; Santini D; Cavani A; Muda AO
    PLoS One; 2012; 7(9):e43110. PubMed ID: 23028444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
    Oon ML; Thike AA; Tan SY; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of
    Strati A; Nikolaou M; Georgoulias V; Lianidou ES
    Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CD44
    Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
    Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.